Core Viewpoint - Centene Corporation is facing a class action securities lawsuit due to alleged securities fraud that affected investors between December 12, 2024, and June 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Centene's management provided overly positive statements while concealing material adverse facts regarding the company's enrollment and morbidity rates [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [2] - Following this announcement, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A securities class-action lawsuit has been filed against Centene Corporation, alleging that the company misrepresented its financial health and market conditions to investors [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, targets investors who purchased Centene securities between December 12, 2024, and June 30, 2025 [1]. - The complaint claims that Centene's leadership provided a misleadingly optimistic view of projected revenue growth, strong enrollment, and low morbidity levels, which contradicted internal data [2]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 financial guidance after an independent actuarial review indicated that market growth was "lower than expected" and morbidity levels were "materially inconsistent" with prior assumptions, leading to a stock price drop of over 40% [3]. - Following the lawsuit, Centene reported a Q2 diluted loss per share of -$0.51, attributed to reduced revenue estimates [4]. Group 3: Investigation and Whistleblower Information - Hagens Berman, a national plaintiffs' rights law firm, is investigating claims on behalf of investors who suffered losses, focusing on whether Centene misrepresented its marketplace business health [5]. - The firm encourages whistleblowers with non-public information about Centene to come forward, offering potential rewards of up to 30% of any successful SEC recovery [5].

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Summary by Sections Class Action Details - The class period for the lawsuit is from December 12, 2024, to June 30, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1][4]. Allegations and Impact - The complaint alleges that Centene's management made overwhelmingly positive statements while concealing material adverse facts about the company's performance [3]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% [3]. Next Steps for Shareholders - The deadline for shareholders to register for the class action is September 8, 2025 [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states served by Centene [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Summary by Relevant Sections Allegations - The complaint claims that Centene's management made overly positive statements while concealing adverse facts about the company's true enrollment and morbidity rates [3]. - On July 1, 2025, Centene announced a withdrawal of its 2025 guidance, revealing that its market growth across 22 states was lower than expected, affecting 72% of its marketplace membership [3]. - The revised guidance indicated a reduction to approximately $1.8 billion in revenue and an adjusted diluted EPS of $2.75 [3]. Stock Performance - Following the announcement on July 1, 2025, Centene's stock price plummeted from $56.65 per share to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Class Action Details - The class period for the lawsuit is defined as December 12, 2024, to June 30, 2025 [3]. - Shareholders are encouraged to register for the class action by September 8, 2025, to potentially be appointed as lead plaintiffs [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Law Firm Information - The Gross Law Firm is leading the class action and is recognized for protecting investors' rights against deceit and fraud [5].

Core Viewpoint - Centene Corporation experienced a significant decline in stock price following the release of disappointing Q2 2025 financial results, leading to a class action lawsuit from investors alleging misleading statements about the company's financial health and market conditions [1][2][4]. Financial Performance - Centene reported a GAAP diluted loss per share of -$0.51 for Q2 2025, primarily due to a reduction in the company's net 2025 Marketplace risk adjustment revenue transfer estimate [4]. - The company withdrew its 2025 financial guidance on July 1, 2025, after a review revealed lower-than-expected market growth and higher morbidity levels than previously assumed, resulting in a stock price drop of over 40% [6]. Legal Issues - A class action lawsuit, Lunstrum v. Centene Corporation, has been filed, representing investors who acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [2][4]. - The lawsuit claims that Centene's leadership misled investors by presenting an overly optimistic view of the company's financial health, despite internal data indicating lower enrollment and higher morbidity rates [5][7]. Market Conditions - Centene's public statements had previously suggested expanding market share and robust business performance, particularly in serving underinsured and uninsured populations, which the lawsuit argues were not aligned with actual operational metrics [5][7]. - A preliminary analysis indicated that more than two-thirds of Centene's Marketplace share showed lower-than-expected enrollment, contradicting the company's optimistic reports [5].

DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Centene's marketplace share showed lower-than-anticipated enrollment and increased aggregate market morbidity; and (2) as a result, Defendants' statements about the company's busines ...

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, leading to a significant drop in stock price after the withdrawal of its 2025 guidance [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Centene's management made overly positive statements while concealing adverse facts about the company's performance [1]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, resulting in a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [1]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% [1]. Group 2: Class Action Details - Shareholders who purchased shares during the class period from December 12, 2024, to June 30, 2025, are encouraged to register for the class action, with a deadline set for September 8, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle, and there is no cost or obligation to participate [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Centene Corporation ("Centene" or the "Company") (NYSE: CNC) between December 12, 2024 and June 30, 2025, inclusive. Should You Join This Class Action Lawsuit? If you purchased or acquired Centene securities, and/or would like to discuss your legal rights and options please visit Centene Co ...